These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35071495)

  • 1. Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy.
    Wang Y; Chen P; Huang J; Liu M; Peng D; Li Z; Chen T; Hong S; Zhou Y
    Ann Transl Med; 2021 Dec; 9(24):1801. PubMed ID: 35071495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 3. Thoracic sarcopenia was a poor prognostic predictor in patients receiving immunotherapy retain-->for advanced non-small-cell retain-->lung cancer.
    Wang M; Yang P; Zhou L; Feng Z
    Acad Radiol; 2024 Aug; ():. PubMed ID: 39181824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive impact of sarcopenia in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A retrospective study.
    Feng Y; Wang L; Guo F; Zhu F; Shi J; Wang Y; Zhang Y; Chen X; Zhang L
    Heliyon; 2024 Mar; 10(5):e27282. PubMed ID: 38463845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Li S; Liu Z; Ren Y; Liu J; Lv S; He P; Yang Y; Sun Y; Chang J; Luo D; Cong M
    Front Nutr; 2022; 9():900823. PubMed ID: 35923193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
    Chen BB; Liang PC; Shih TT; Liu TH; Shen YC; Lu LC; Lin ZZ; Hsu C; Hsu CH; Cheng AL; Shao YY
    Eur Radiol; 2023 Jan; 33(1):512-522. PubMed ID: 35864351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer.
    Minami S; Ihara S; Tanaka T; Komuta K
    World J Oncol; 2020 Feb; 11(1):9-22. PubMed ID: 32095185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
    Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
    Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer.
    Mahajan A; Goyal D; Agarwal U; Patil V; Shukla S; Noronha V; Joshi A; Menon N; Prabhash K
    Explor Target Antitumor Ther; 2023; 4(5):896-911. PubMed ID: 37970209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcopenia defined by skeletal muscle mass index at the third lumbar vertebra is a prognostic factor for extensive-stage small cell lung cancer patients: a retrospective study.
    Wang K; Long W; Sima X; Zhao Y; Xiao B; Gulizeba H; Huang Y
    J Thorac Dis; 2022 Jul; 14(7):2645-2651. PubMed ID: 35928624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
    Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
    Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy.
    Bolte FJ; McTavish S; Wakefield N; Shantzer L; Hubbard C; Krishnaraj A; Novicoff W; Gentzler RD; Hall RD
    Front Oncol; 2022; 12():986236. PubMed ID: 36212442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
    Soyano AE; Dholaria B; Marin-Acevedo JA; Diehl N; Hodge D; Luo Y; Manochakian R; Chumsri S; Adjei A; Knutson KL; Lou Y
    J Immunother Cancer; 2018 Nov; 6(1):129. PubMed ID: 30470260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between changes in thioredoxin reductase and other peripheral blood biomarkers with response to PD-1 inhibitor-based combination immunotherapy in non-small cell lung cancer: a retrospective study.
    Wen S; Du X; Chen Y; Xia J; Wang R; Zhu M; Peng W; Spitaleri G; Hofman P; Bironzo P; Wang X; Shen B
    Transl Lung Cancer Res; 2022 May; 11(5):757-775. PubMed ID: 35693285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.
    Shiroyama T; Nagatomo I; Koyama S; Hirata H; Nishida S; Miyake K; Fukushima K; Shirai Y; Mitsui Y; Takata S; Masuhiro K; Yaga M; Iwahori K; Takeda Y; Kida H; Kumanogoh A
    Sci Rep; 2019 Feb; 9(1):2447. PubMed ID: 30792455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.